This study systematically reveals the dynamics of antibody affinity maturation and transplacental transfer induced by maternal RSV vaccination, providing critical empirical evidence for optimizing immunoprotection strategies in preterm infants, with direct implications for the timing of perinatal immunization interventions.
Literature Overview
The article titled 'Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity,' published in the journal Nature Communications, systematically investigates the quality, affinity maturation, and transfer efficiency of antibody responses following maternal RSV vaccination during pregnancy. By quantifying neutralizing antibodies, binding antibodies, and affinity kinetics, the study demonstrates that vaccine-induced high-level, high-affinity antibodies are efficiently transferred across the placenta to newborns, particularly highlighting the limited antibody transfer in preterm infants. These findings provide mechanistic insights into optimizing maternal immunization strategies.Background Knowledge
Respiratory syncytial virus (RSV) is the leading pathogen causing acute lower respiratory tract infections in children under five years of age worldwide, resulting in approximately 33 million infections and 50,000 to 100,000 deaths annually. Infants, especially preterm infants, are at high risk of developing severe pneumonia or bronchiolitis due to immature immune systems and narrow airways, making RSV a leading cause of pediatric hospitalization. Although monoclonal antibodies (e.g., nirsevimab) are available for passive immunization in newborns, maternal active immunization offers greater cost-effectiveness and broader population coverage. Current RSV vaccine development focuses on the prefusion conformation (preF) of the fusion (F) protein, which exposes multiple neutralizing epitopes (such as site Ø and V), while the G protein exhibits high variability and weak immunogenicity. However, the quality of antibodies induced by maternal vaccination—particularly the extent of affinity maturation and transfer efficiency across different gestational weeks—remains poorly understood. This study addresses a critical knowledge gap by systematically evaluating the immune response to the Abrysvo vaccine in a real-world pregnant cohort, with a focus on antibody affinity maturation, transplacental transfer kinetics, and their relationship with gestational age at delivery, thereby providing scientific support for optimizing vaccination timing.
Research Methods and Experiments
The study included paired maternal and cord blood samples from 107 pregnant women (58 unvaccinated, 49 vaccinated with Abrysvo) collected within 72 hours of delivery. RSV-Luciferase neutralization tests (RSV-LINT) were used to measure neutralizing antibody titers against RSV-A2 and RSV-B1 strains. Surface plasmon resonance (SPR) was employed to analyze the binding kinetics and affinity (dissociation constant) of antibodies to the preF protein. Multiplex microsphere immunoassays (Luminex) quantified IgG binding antibody levels against preF and G proteins. Participants were further stratified by gestational age at birth (preterm <34 weeks, late preterm 34–36 weeks, early term 37–38 weeks, full term ≥39 weeks) to assess the relationship between antibody transfer efficiency and gestational age.Key Conclusions and Perspectives
Research Significance and Prospects
This study is the first to systematically demonstrate that maternal RSV vaccination not only increases antibody quantity but also significantly enhances antibody quality (affinity), with efficient transfer to the fetus. It introduces a new dimension to understanding passive immunity—high-affinity antibodies may offer more effective viral neutralization, longer half-lives, and improved protective efficacy.
The findings clearly indicate that antibody transfer is suboptimal in preterm infants due to insufficient transfer time, suggesting that the current 32–36 week vaccination window may be inadequate for this high-risk group. Future studies should explore earlier vaccination windows (e.g., 28–32 weeks), balancing preterm birth risks with immune response development. Furthermore, antibody affinity could serve as a potential correlate of protection (CoP) in future vaccine evaluations, guiding the design of next-generation vaccines.
Conclusion
This study provides critical mechanistic evidence for maternal RSV immunization strategies: the Abrysvo vaccine induces high-level, high-affinity neutralizing antibodies in pregnant women, which are efficiently transferred across the placenta to newborns, offering passive immunity during early life. The study particularly reveals that preterm infants have lower antibody levels due to insufficient transfer time, suggesting that the current 32–36 week vaccination strategy may require individualized adjustments for high-risk pregnancies. The discovery of affinity maturation as a new dimension expands the traditional immune evaluation framework that relies solely on neutralization titers, offering a more sensitive metric for vaccine optimization and protection prediction. From bench to bedside, this study supports integrating maternal vaccination into routine perinatal care, especially in regions with high RSV prevalence, to significantly reduce infant hospitalization burdens. Future research should incorporate real-world effectiveness data to further validate the correlation between antibody affinity and clinical protection, and explore optimal vaccination timing to maximize immune benefits for all newborns, particularly preterm infants.
